Biocept Inc is an early commercial-stage molecular oncology diagnostics company. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's lung, breast, and gastric cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients based on detailed data on the characteristics of tumors. Its products include CEE-Sure BCT, and Target Selector Kits. Geographically, it operates through the United States, which is also the revenue generation region for the group.
| Website: | www.biocept.com |
| Main Phone: | +1 858 320-8200 |
| Address: | 5810 Nancy Ridge Drive |
| Address 2: | Suite 150 |
| State: | CA |
| City / Town: | San Diego |
| Country: | USA |
| Postal Code: | 92121 |
| Exchange: | NSC |
| CEO: | Michael W. Nall |
| Employees: | 87 |
| NAICS: | Medical Laboratories(621511) |
Target Selector kits are research-use-only (RUO), to enable labs to leverage Biocept's patented assay technology for liquid biopsy testing
SGEN adds CASC's late stage breast cancer therapeutic pipeline.
Biocept Inc. (BIOC) has patented molecular diagnostic technology that uses an antibody to detect circulating tumor cells (CTCs)
Many tissue biopsies for lung cancer don’t give doctors the answers they need. Biocept's liquid biopsy technology could change all of that.
The full IPO calendar is available at IPOpremium.com Ranked by size of IPO, largest first. (1) Real estate finance Based in New York, NY, Ladder Capital ($LADR) scheduled a $225 million IPO on the
Biocept (BIOC) is an early-stage cancer diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, tests utilizing a
At www.ValuEngine.com we show that the Medical sector is 9.8% overvalued. The Medical Products industry is 4.2% overvalued. The Medical Services industry is 9.1% overvalued. The Medical
Biocept Inc is an early commercial-stage molecular oncology diagnostics company. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's lung, breast, and gastric cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients based on detailed data on the characteristics of tumors. Its products include CEE-Sure BCT, and Target Selector Kits. Geographically, it operates through the United States, which is also the revenue generation region for the group.
| Website: | www.biocept.com |
| Main Phone: | +1 858 320-8200 |
| Address: | 5810 Nancy Ridge Drive |
| Address 2: | Suite 150 |
| State: | CA |
| City / Town: | San Diego |
| Country: | USA |
| Postal Code: | 92121 |
| Exchange: | NSC |
| CEO: | Michael W. Nall |
| Employees: | 87 |
| NAICS: | Medical Laboratories(621511) |
Target Selector kits are research-use-only (RUO), to enable labs to leverage Biocept's patented assay technology for liquid biopsy testing
SGEN adds CASC's late stage breast cancer therapeutic pipeline.
Biocept Inc. (BIOC) has patented molecular diagnostic technology that uses an antibody to detect circulating tumor cells (CTCs)
Many tissue biopsies for lung cancer don’t give doctors the answers they need. Biocept's liquid biopsy technology could change all of that.
The full IPO calendar is available at IPOpremium.com Ranked by size of IPO, largest first. (1) Real estate finance Based in New York, NY, Ladder Capital ($LADR) scheduled a $225 million IPO on the
Biocept (BIOC) is an early-stage cancer diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, tests utilizing a
At www.ValuEngine.com we show that the Medical sector is 9.8% overvalued. The Medical Products industry is 4.2% overvalued. The Medical Services industry is 9.1% overvalued. The Medical
| Last Price 0.35 | Change $ -0.0014 | Change % -0.40 | Tick N/A |
| Bid 0.35 | Bid Size 49,500.00 | Ask 0.35 | Ask Size 1,800.00 |
| Open 0.36 | High 0.36 | Low 0.34 | Prev Close 0.35 |
| Last Trade | Volume 4.2 mi | 52 Wk Hi 2.50 | 52 Wk Low 0.23 |
| Market Cap 14.7 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 42,218,235.00 | EPS (TTM) -1.98 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 2 |
| Number of Buys | 0 | 2 |
| Number of Sells | 0 | 0 |
| Net Activity | 0 | 50000 |
| Last 10 Buys | Shares |
|---|---|
| Bruce E. Gerhardt | 1,000 |
| Bruce E. Gerhardt | 1,000 |
| David F. Hale | 1,000 |
| David F. Hale | 1,000 |
| Edward Neff | 1,000 |
| Bruce E. Gerhardt | 1,000 |
| Bruce E. Gerhardt | 1,000 |
| Edward Neff | 1,000 |
| Veena Singh | 1,000 |
| Veena Singh | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Jeffrey H. Berg | 1,000 |
| David Pitler | 1,000 |
| David Pitler | 1,000 |
| David Pitler | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 0.65 | 0.65 | 0.65 | 0.65 |
| Low Target Price Estimate | 0.65 | 0.65 | 0.65 | 0.65 |
| Mean Target Price Estimate | 0.65 | 0.65 | 0.65 | 0.65 |
| Standard Deviation | 0 | 0 | 0 | 0 |
| Date of Most Recent Estimate | 04/03/18 | 04/03/18 | 04/03/18 | 04/03/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-06 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 108 | 2018-05-29 |
| 424B3 | Prospectus filed under Rule 424(b)(3) | 25 | 2018-05-24 |
| EFFECT | Notice from the SEC of registration effectiveness | 1 | 2018-05-24 |
| S-1 | General form for registration of securities under the Securities Act of 1933 | 60 | 2018-05-23 |
| PRE 14A | Preliminary proxy statement providing notification matters to be brought to a vote | 110 | 2018-05-17 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 66 | 2018-05-15 |
| S-3 | Simplified registration form | 160 | 2018-05-15 |
| 8-K | Report of unscheduled material events or corporate changes. | 8 | 2018-05-15 |
| 10-K/A | Amendment to a previously filed 10-K | 41 | 2018-04-30 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 2 | 1 | 1 | 1 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait